It has been reported that the recombinant Mesd protein and its C-terminal region peptide, two antagonists of LRP6, markedly suppressed Wnt/β-catenin signaling, cell proliferation and tumor growth in breast cancer [38]. Here, LRP6 is linked to breast carcinoma.